Caregivers of children with Dravet syndrome report that their child’s use of Fintepla (fenfluramine) significantly reduces seizure burden and leads to a number of quality-of-life benefits for their children, themselves, and the rest of their family. That’s according to a recent study conducted in Europe, which involved interviews…
News
Fintepla (fenfluramine) is associated with dose-dependent, clinically meaningful improvements in everyday behavioral and emotional control, as well as the ability to adapt to new situations, in preschool-aged children with Dravet syndrome. These benefits weren’t always tied to a clinically meaningful reduction in the frequency of seizures, suggesting the…
Long-term use of the sodium channel blocker phenytoin led to reductions in seizure frequency for four male patients with Dravet syndrome, according to a study in Australia. Weaning off the medication caused seizures to worsen, and re-starting it lowered seizure frequency and improved alertness. The findings are in…
IAMA Therapeutics has signed a second agreement with PsychoGenics to test the effectiveness of new therapy candidates in Dravet syndrome animal models. The companies entered into a service agreement last year to identify the effectiveness of new drug candidates…
New safety and efficacy data from two Phase 1/2a clinical trials testing STK-001, Stoke Therapeutics’ investigational treatment for children and adolescents with Dravet syndrome, are expected as early as mid-year. Interim results from the ongoing Phase 1/2a MONARCH (NCT04442295) and ADMIRAL (ISRCTN99651026) trials, reported late last…
The efficacy and safety of Epidiolex, an oral cannabidiol, in children and adults with Dravet syndrome and Lennox-Gastaut syndrome (LGS) were supported in a real-world setting, with benefits similar to those seen in previous clinical trials and expanded access programs (EAPs), a Spanish EAP study reported. EAPs are…
A novel gene therapy that works to increase the levels of an enzyme called p38-gamma extended survival and reduced seizure activity in a mouse model of Dravet syndrome, a new study reports. “We have tested this therapy extensively, and rigorous assessment by independent labs has confirmed our results,” said…
The Dravet Syndrome Foundation (DSF) has announced the award of $690,000 in total research funding for five projects that aim to improve care for people with Dravet syndrome. The one- to two-year research grants will provide each project funding in amounts ranging from $75,000 to $165,000. Two of…
Up to three years of treatment with Epidiolex in a clinical trial led to sustained reductions in seizure frequency — with the oral cannabidiol generally well-tolerated — in children and adults with seizures associated with tuberous sclerosis complex (TSC). That’s according to final data from an open-label extension…
Combining Xcopri (cenobamate) with existing antiseizure medications may significantly reduce the frequency of seizures in adults with Dravet syndrome, according to a report of four patients. The oral medication — marketed as Ontozry in Europe — reduced the frequency of seizures in all four adults by…
Recent Posts
- Language difficulties vary widely in Dravet syndrome kids
- Resetting the clock on my daughter’s stretch of seizure freedom
- Extreme heat may worsen seizure risk in children with Dravet, study says
- After a tragedy, I’m trying to restore the magic of Halloween for my children
- Apprehension turns to high-fives on my daughter’s cheer squad